Abstract
<b>Introduction:</b> Mesothelioma is a heterogenous disease with variable phenotype and survival. Clinical trials are often affected by selection bias, which can reduce generalisability. <b>Aim:</b> ASSESS-meso is a multi-centre, prospective, longitudinal mesothelioma cohort. This interim analysis, conducted when recruitment reached 25%, evaluated external validity by comparing participant characteristics with real-world and clinical trial cohorts. <b>Methods:</b> All capacitous mesothelioma patients seen at 13 recruiting sites were eligible for ASSESS-meso. Clinical, radiological and biochemical data were collected, alongside patient-reported symptom scores. Biological samples were stored for future research. Data from the 2020 UK National Mesothelioma Audit<sup>1</sup> (real-world cohort) and CHECKMATE-743 trial<sup>2</sup> (clinical trial cohort) were used as comparators. <b>Results:</b> Between 04/07/2017-20/12/2021, 224 patients enrolled. As shown in Table 1, ASSESS-meso participants were closer to the real-world population in age, performance status, disease site and stage than the clinical trial population. ASSESS-meso had fewer participants with unspecified histology and more epithelioid disease than the real-world cohort. <b>Conclusion:</b> ASSESS-meso is representative of the UK mesothelioma population. Future studies reporting symptoms, radiological and biochemical outcomes will help characterise the different mesothelioma phenotypes with high external validity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
